Health23 hours ago
Alnylam Launches Phase 3 Trial for Zilebesiran Despite Setbacks
Alnylam Pharmaceuticals has announced the initiation of a Phase 3 cardiovascular outcomes trial for its hypertension therapy, zilebesiran, later this year. This decision comes despite recent...
